TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051

Completed

Brief Summary: This is an observational, "ancillary study" intended to describe opioid use among opioid use disorder patients following their discharge into the community from inpatient detoxification and/or short-term residential treatment programs affiliated with parent study CTN-0051, which assessed the comparative effectiveness of extended release injectable naltrexone (XR-NTX, Vivitrol®), an opioid antagonist recently approved and indicated for the prevention of relapse to opioid dependence, versus buprenorphine-naloxone (BUP-NX, Suboxone®), a high affinity partial agonist indicated for maintenance treatment of opioid dependence, as pharmacotherapeutic aids to recovery.

Detailed Description: Participant recruitment will begin after recruitment for CTN-0051 has been completed. Opioid use disorder patients will be recruited prior to leaving detoxification and/or short-term residential programs. Screening and baseline data (focused on demographics, diagnosis and service utilization) will be collected prior to discharge, and follow-up data (focused on opioid use) will be collected at weeks 1, 4 and 8 following discharge.

Recruitment & Eligibility

Inclusion Criteria

18 years or older;
Meet DSM-5 criteria for opioid-use disorder (heroin or prescription opioids);
Have used opioids other than as specifically prescribed within thirty days prior to consent
Seeking treatment for opioid dependence;
Able to provide written informed consent;
Able to speak English sufficiently to understand the study procedures.

Exclusion Criteria

Serious medical, psychiatric or substance use disorder that, in the opinion of the Site PI, would make participation hazardous to the participant, compromise study findings or prevent the participant from completing the study;
Suicidal or homicidal ideation that requires immediate attention;
Maintenance on methadone at doses of 30mg or greater at the time of signing consent;
Presence of pain of sufficient severity as to require ongoing pain management with opioids;
Pending legal action or other reasons that might prevent an individual from completing the study;
If female, currently pregnant or breastfeeding or planning on conception;
Prior participation in parent trial CTN-0051

Arm && Interventions

Group	Intervention	Description
Opioid Use Disorder Patients	Treatment As Usual	-

Primary Outcome Measures

Name	Time	Method
Positive UDSs at Week 4	week 4	Number of positive UDSs at Week 4
Time to First Use	Up to Week 8 Post Discharge	Days to first opioid use from Timeline Followback
Days of Opioid Use	Up to Week 8 Post Discharge	Days of use up 8 weeks post discharge
Negative UDSs at Week 8	week 8	Number of negative UDSs at Week 8
Positive Urine Drug Screen (UDS) at Week 1	week 1	Number of positive UDSs at Week 1
Missing UDSs at Week 1	week 1	Number of missing UDSs at Week 1
Missing UDSs at Week 4	week 4	Number of missing UDSs at Week 4
Negative UDSs at Week 1	week 1	Number of negative UDSs at Week 1
Negative UDSs at Week 4	week 4	Number of negative UDSs at Week 4
Time to Regular Use	Up to Week 8 Post Discharge	Days to regular opioid use from Timeline Followback
Missing UDSs at Week 8	week 8	Number of missing UDSs at Week 8
Positive UDSs at Week 8	week 8	Number of positive UDSs at Week 8

Secondary Outcome Measures

Name	Time	Method

Locations (5): Bellevue Hospital
🇺🇸
New York, New York, United States
Maryhaven
🇺🇸
Columbus, Ohio, United States
Gateway Community Services, Inc.
🇺🇸
Jacksonville, Florida, United States
Stanley Street Treatment and Resources
🇺🇸
Fall River, Massachusetts, United States
Tarzana Treatment Centers
🇺🇸
Tarzana, California, United States